Docstoc

Pipeline Review, H2 2012 Xerosis (Dry Skin)

Document Sample
Pipeline Review, H2 2012 Xerosis (Dry Skin) Powered By Docstoc
					RnR Market Research Offers “Xerosis (Dry Skin) – Pipeline Review, H2 2012”
Report at US$2000 (Single User License). The report got published in Oct 2012 and contains 24
Pages.




Xerosis (Dry Skin) – Pipeline Review, H2 2012

Get your copy of this report @ http://www.rnrmarketresearch.com/xerosis-dry-skin-pipeline-
review-h2-2012-market-report.html

Summary

Global Markets Direct‟s, „Xerosis (Dry Skin) – Pipeline Review, H2 2012′, provides an overview of
the indication‟s therapeutic pipeline. This report provides information on the therapeutic
development for Xerosis (Dry Skin), complete with latest updates, and special features on late-
stage and discontinued projects. It also reviews key players involved in the therapeutic
development for Xerosis (Dry Skin). Xerosis (Dry Skin) – Pipeline Review, Half Year is built using
data and information sourced from Global Markets Direct‟s proprietary databases,
Company/University websites, SEC filings, investor presentations and featured press releases
from company/university sites and industry-specific third party sources, put together by Global
Markets Direct‟s team.

Note*: Certain sections in the report may be removed or altered based on the availability and
relevance of data for the indicated disease.

Scope

- A snapshot of the global therapeutic scenario for Xerosis (Dry Skin).
- A review of the Xerosis (Dry Skin) products under development by companies and
universities/research institutes based on information derived from company and industry-specific
sources.
- Coverage of products based on various stages of development ranging from discovery till
registration stages.
- A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
- Coverage of the Xerosis (Dry Skin) pipeline on the basis of route of administration and molecule
type.
- Key discontinued pipeline projects.
- Latest news and deals relating to the products.
Reasons to buy

- Identify and understand important and diverse types of therapeutics under development for
Xerosis (Dry Skin).
- Identify emerging players with potentially strong product portfolio and design effective counter-
strategies to gain competitive advantage.
- Plan mergers and acquisitions effectively by identifying players of the most promising pipeline.
- Devise corrective measures for pipeline projects by understanding Xerosis (Dry Skin) pipeline
depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners
with the most attractive projects to enhance and expand business potential and scope.
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors
that drove them from pipeline.

Table of Contents

Introduction 4
Global Markets Direct Report Coverage 4
Xerosis (Dry Skin) Overview 5
Therapeutics Development 6
An Overview of Pipeline Products for Xerosis (Dry Skin) 6
Xerosis (Dry Skin) Therapeutics under Development by Companies 8
Late Stage Products 9
Comparative Analysis 9
Discovery and Pre-Clinical Stage Products 10
Comparative Analysis 10
Xerosis (Dry Skin) Therapeutics - Products under Development by Companies 11
Companies Involved in Xerosis (Dry Skin) Therapeutics Development 12
Syntopix Group Plc 12
Pierre Fabre Medicament 13
Xerosis (Dry Skin) - Therapeutics Assessment 14
Assessment by Monotherapy Products 14
Assessment by Route of Administration 15
Drug Profiles 17
HO/04/08 - Drug Profile 17
Product Description 17
Mechanism of Action 17
R&D Progress 17
V0034-CR01B - Drug Profile 18
Product Description 18
Mechanism of Action 18
R&D Progress 18
Emollient-1 - Drug Profile 19
Product Description 19
Mechanism of Action 19
R&D Progress 19
Emollient-2 - Drug Profile 20
Product Description 20
Mechanism of Action 20
R&D Progress 20
Emollient-3 - Drug Profile 21
Product Description 21
Mechanism of Action 21
R&D Progress 21
Xerosis (Dry Skin) Therapeutics - Dormant Products 22
Appendix 23
Methodology 23
Coverage 23
Secondary Research 23
Primary Research 23
Expert Panel Validation 23
Contact Us 24
Disclaimer 24

List of Tables
Number of Products Under Development for Xerosis (Dry Skin), H2 2012 6
Products under Development for Xerosis (Dry Skin) - Comparative Analysis, H2 2012 7
Number of Products under Development by Companies, H2 2012 8
Comparative Analysis by Late Stage Development, H2 2012 9
Comparative Analysis by Discovery and Pre-Clinical Stage Development, H2 2012 10
Products under Development by Companies, H2 2012 11
Syntopix Group Plc, H2 2012 12
Pierre Fabre Medicament, H2 2012 13
Assessment by Monotherapy Products, H2 2012 14
Assessment by Stage and Route of Administration, H2 2012 16
Xerosis (Dry Skin) Therapeutics - Dormant Products 22

List of Figures
Number of Products under Development for Xerosis (Dry Skin), H2 2012 6
Products under Development for Xerosis (Dry Skin) - Comparative Analysis, H2 2012 7
Products under Development by Companies, H2 2012 8
Late Stage Products, H2 2012 9
Discovery and Pre-Clinical Stage Products, H2 2012 10
Assessment by Monotherapy Products, H2 2012 14
Assessment by Route of Administration, H2 2012 15
Assessment by Stage and Route of Administration, H2 2012 16


For more details contact Mr. Priyank Tiwari: sales@rnrmarketresearch.com / +18883915441

Website: http://www.rnrmarketresearch.com/

				
DOCUMENT INFO
Categories:
Stats:
views:13
posted:11/21/2012
language:
pages:4
Description: This report provides information on the therapeutic development for Xerosis (Dry Skin), complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Xerosis (Dry Skin). Xerosis (Dry Skin) – Pipeline Review, Half Year is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.